Применение статинов у пациентов с хроническими заболеваниями печени: плейотропные эффекты и современные данные доказательной медицины. Обзор доказательной базы
Применение статинов у пациентов с хроническими заболеваниями печени: плейотропные эффекты и современные данные доказательной медицины. Обзор доказательной базы
М.В. Леонова. Применение статинов у пациентов с хроническими заболеваниями печени: плейотропные эффекты и современные данные доказательной медицины.
Обзор доказательной базы. Справочник поликлинического врача. 2019; 6: 8–11.
Обзор доказательной базы. Справочник поликлинического врача. 2019; 6: 8–11.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Статины – класс препаратов, эффективно снижающих уровень холестерина
и липопротеидов низкой плотности (ЛПНП) путем ингибирования ГМГ-КоА-редуктазы.
и липопротеидов низкой плотности (ЛПНП) путем ингибирования ГМГ-КоА-редуктазы.
Список литературы
1. Chou R, Dana T, Blazina I et al. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2016; 316 (19): 2008–24.
2. Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 88 (10059): 2532–61.
3. Bays H, Cohen DE, Chalasani N et al; The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 2014; 8 (Suppl. 3): S47–57.
4. De Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004; 24 (5): 584–91.
5. Trebicka J, Schierwagen R. Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension. Gut 2015; 64 (9): 1349–50.
6. Vargas JI, Arrese M, Shah VH, Arab JP. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects. Curr Gastroenterol Rep 2017; 19 (9): 43.
7. De Keyser CE, Koehler EM, Schouten JN et al. Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. Dig Liver Dis 2014; 46: 720–25.
8. Dongiovanni P, Petta S, Mannisto V et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63 (3):
705–12.
9. Eslami L, Merat S, Malekzadeh R et al. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2013; 12: CD008623.
10. Sigler MA, Congdon L, Edwards KL. An evidence-based review of statin use in patients with nonalcoholic fatty liver disease. Clin Med Insights Gastroenterol 2018; 11: 1–9.
11. Nakahara T, Hyogo H, Kimura Y et al. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res 2012; 42 (11): 1065–72.
12. Hyogo H, Ikegami T, Tokushige K et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res 2011; 41 (11): 1057–65.
13. Athyros VG, Boutari C, Stavropoulos K et al. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Curr Vasc Pharmacol 2018; 16 (3): 246–53.
14. Rattanachaisit P, Susantitaphong P, Thanapirom K et al. Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Asian Biomed (Res Rev News) 2018; 12 (1): 3–13.
15. Kamal S, Khan MA, Seth A et al. Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis. Am J Gastroenterol 2017; 112: 1495–505.
16. Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 1521–30.
17. Ma X, Sun D, Li C et al. Statin use and virus-related cirrhosis: A systemic review and meta-analysis. Clin Res Hepatol Gastroenterol 2017; 41 (5): 533–42.
18. Abraldes JG, Albillos A, Banares R et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136: 1651–8.
19. Pollo-Flores P, Soldan M, Santos UC et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig Liver Dis 2015; 47: 957–63.
20. Abraldes JG, Villanueva C, Aracil C et al. Group BS. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 2016; 150: 1160–70.
21. Bishnu S, Ahammed SM, Sarkar A et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. Eur J Gastroenterol Hepatol 2018; 30: 54–9.
22. Lee TY, Wu JC, Yu SH et al. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Int J Cancer 2017; 141 (7): 1307–14.
23. Kim G, Jang SY, Nam CM, Kang ES. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study. J Hepatol 2018; 68: 476–84.
24. Singh S, Singh PP, Singh AG et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013; 144 (2): 323–32.
25. LaBrecque DR, Abbas Z, Anania F et al. World Gastroenterology Organisation. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol 2014; 48 (6): 467–73.
2. Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 88 (10059): 2532–61.
3. Bays H, Cohen DE, Chalasani N et al; The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 2014; 8 (Suppl. 3): S47–57.
4. De Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004; 24 (5): 584–91.
5. Trebicka J, Schierwagen R. Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension. Gut 2015; 64 (9): 1349–50.
6. Vargas JI, Arrese M, Shah VH, Arab JP. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects. Curr Gastroenterol Rep 2017; 19 (9): 43.
7. De Keyser CE, Koehler EM, Schouten JN et al. Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. Dig Liver Dis 2014; 46: 720–25.
8. Dongiovanni P, Petta S, Mannisto V et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63 (3):
705–12.
9. Eslami L, Merat S, Malekzadeh R et al. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2013; 12: CD008623.
10. Sigler MA, Congdon L, Edwards KL. An evidence-based review of statin use in patients with nonalcoholic fatty liver disease. Clin Med Insights Gastroenterol 2018; 11: 1–9.
11. Nakahara T, Hyogo H, Kimura Y et al. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res 2012; 42 (11): 1065–72.
12. Hyogo H, Ikegami T, Tokushige K et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res 2011; 41 (11): 1057–65.
13. Athyros VG, Boutari C, Stavropoulos K et al. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Curr Vasc Pharmacol 2018; 16 (3): 246–53.
14. Rattanachaisit P, Susantitaphong P, Thanapirom K et al. Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Asian Biomed (Res Rev News) 2018; 12 (1): 3–13.
15. Kamal S, Khan MA, Seth A et al. Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis. Am J Gastroenterol 2017; 112: 1495–505.
16. Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 1521–30.
17. Ma X, Sun D, Li C et al. Statin use and virus-related cirrhosis: A systemic review and meta-analysis. Clin Res Hepatol Gastroenterol 2017; 41 (5): 533–42.
18. Abraldes JG, Albillos A, Banares R et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136: 1651–8.
19. Pollo-Flores P, Soldan M, Santos UC et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig Liver Dis 2015; 47: 957–63.
20. Abraldes JG, Villanueva C, Aracil C et al. Group BS. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 2016; 150: 1160–70.
21. Bishnu S, Ahammed SM, Sarkar A et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. Eur J Gastroenterol Hepatol 2018; 30: 54–9.
22. Lee TY, Wu JC, Yu SH et al. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Int J Cancer 2017; 141 (7): 1307–14.
23. Kim G, Jang SY, Nam CM, Kang ES. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study. J Hepatol 2018; 68: 476–84.
24. Singh S, Singh PP, Singh AG et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013; 144 (2): 323–32.
25. LaBrecque DR, Abbas Z, Anania F et al. World Gastroenterology Organisation. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol 2014; 48 (6): 467–73.
Авторы
М.В. Леонова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.